← Back to all trials
Recruiting
NCT05672654
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
Conditions: HIV Seropositivity, Immunodeficiency, Vaccination Reaction, Covid19
Sex: All
Ages: 16 Years – 100 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 600
Sponsor: University Hospital, Ghent
Location: Belgium
Summary
The aim of this study is to identify both the humoral immunological response through the detection of induced antibodies and the cellular immunological response through the detection of interferon gamma production by functional CD4+ and CD8+ cells in different groups of immunocompromised patients.
For antibody detection, LIAISON® SARS-CoV-2 TrimericS assay (DiaSorin) will be used and for the evaluation of cellular immunity - QuantiFERON SARS-CoV-2 assay (QIAGEN).
Eligibility Criteria
Inclusion Criteria:Following patient groups receiving the Pfizer vaccineHIV-positive patients with CD4 < 350 cellen/mm3Common variable immunodeficiency disorders en primary immunodeficiency disordersImmune-compromised patients hospitalized at rheumatology/neurology/nephrologyExclusion Criteria:patients receiving a different of vaccine
Source: ClinicalTrials.gov (NCT05672654). StuddyBuddy aggregates publicly available trial information.
